TY - JOUR
T1 - Molecularly targeted therapy for metastatic colon cancer
T2 - Proven treatments and promising new agents
AU - Wu, Christina
AU - Charabaty, Aline
AU - Pishvaian, Michael
AU - Marshall, John L.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2010/10
Y1 - 2010/10
N2 - There has been a dramatic upsurge in the investigation of molecularly targeted therapy in colorectal cancer over the past two decades, with the first success being bevacizumab, a monoclonal antibody directed at vascular endothelial growth factor (VEGF). The latest additions to our armament are epidermal growth factor receptor (EGFR) inhibitors and the discovery of K-ras mutation's impact on treatment efficacy. This review summarizes the new therapies targeting established pathways, such as VEGF and EGFR, and introduces tyrosine kinase inhibitors and monoclonal antibodies, as well as exciting novel agents targeting insulin-like growth factor, tumor necrosis factor, the Sonic Hedgehog pathway, Src kinase, mammalian target of rapamycin, and protein kinase C, which already have shown activity in other cancers and are currently being studied in phase 1/2 trials in metastatic colorectal cancer.
AB - There has been a dramatic upsurge in the investigation of molecularly targeted therapy in colorectal cancer over the past two decades, with the first success being bevacizumab, a monoclonal antibody directed at vascular endothelial growth factor (VEGF). The latest additions to our armament are epidermal growth factor receptor (EGFR) inhibitors and the discovery of K-ras mutation's impact on treatment efficacy. This review summarizes the new therapies targeting established pathways, such as VEGF and EGFR, and introduces tyrosine kinase inhibitors and monoclonal antibodies, as well as exciting novel agents targeting insulin-like growth factor, tumor necrosis factor, the Sonic Hedgehog pathway, Src kinase, mammalian target of rapamycin, and protein kinase C, which already have shown activity in other cancers and are currently being studied in phase 1/2 trials in metastatic colorectal cancer.
KW - Colorectal cancer
KW - Metastatic
KW - Molecular therapy
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=79952737902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952737902&partnerID=8YFLogxK
U2 - 10.1007/s11888-010-0061-2
DO - 10.1007/s11888-010-0061-2
M3 - Review article
AN - SCOPUS:79952737902
VL - 6
SP - 193
EP - 198
JO - Current Colorectal Cancer Reports
JF - Current Colorectal Cancer Reports
SN - 1556-3790
IS - 4
ER -